<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00644579</url>
  </required_header>
  <id_info>
    <org_study_id>CL-1205</org_study_id>
    <secondary_id>EudraCT number: 2007-006738-33</secondary_id>
    <nct_id>NCT00644579</nct_id>
  </id_info>
  <brief_title>bLAC - Treatment of Cutaneous Warts in Immune Suppressed, Kidney Transplanted Patients</brief_title>
  <official_title>bLAC - A Phase II Double-Blind, Placebo Controlled, Clinical Proof of Concept Trial of the Efficacy of 8 Weeks Treatment of Cutaneous Warts With bLAC in Immune Suppressed, Kidney Transplanted Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NatImmune A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NatImmune A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As many as 85 % of renal transplant patients may suffer from viral warts with a high degree
      of treatment resistance. Promising results of hLAC (human lactalbumin complex with lipid)
      point to a beneficial effect without noticeable side effects of bLAC (bovine lactalbumin
      complex with lipid). The aim of first clinical trial with bLAC is to show proof of concept in
      treatment of cutaneous wart lesions on hands and/or feet after local administration of bLAC
      in two dose groups to immune suppressed, kidney transplanted patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">February 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in the area of wart lesions located on fingers and/or palms and/or toes and/or soles of the feet, measured by an objective method by drawing of individual lesions</measure>
    <time_frame>Prospective</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clearance of index wart lesions. Time to clearance of warts. Recurrence rate of previously cleared wart lesions. Occurrence of new warts.overall changes of index warts lesions. Safety and tolerability.</measure>
    <time_frame>Prospective</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cutaneous Warts</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bLAC high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bLAC low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bLAC</intervention_name>
    <description>bLAC high and low dose and placebo</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cutaneous warts on ingers and/or palms and/or toes and/or soles of feet

          -  Common warts and mosaic warts, diagnosed by an experienced dermatologist

          -  Solitary wart lesions or 2 or more lesions per patient

          -  Lesions present for more than 6 months

          -  Men or women, aged 18 or above

          -  History of kidney transplantation and immune suppressive therapy after transplant

          -  Concomitant immune suppressive therapy stable for 6 months prior to randomization

          -  Agreement from patient to allow photographs to be taken and used as part of trial data
             documentation (2 centres)

          -  Women of childbearing potential must have negative pregnancy test at screening and
             must use adequate contraception

          -  Ability to comply with requirements of trial

          -  Written informed consent

        Exclusion Criteria:

          -  Verruca plana lesions

          -  Suspected allergy to milk verified by serum analysis of IgE towards cow milk

          -  Breastfeeding

          -  Any local medication for any purpose other than wart treatment in target area during 4
             weeks prior to randomization and during treatment period

          -  Concomitant treatment with other wart therapies two weeks prior to randomization and
             during trial period

          -  Intolerance towards bovine alpha-lactalbumin, oleic acid or any excipient in the
             formulation

          -  Known HIV infection or any current uncontrolled infection

          -  Any chronic or acute skin condition susceptible of interfering with evaluation of drug
             effect in this trial

          -  Participation in any investigational trial or use of any investigational drug within
             30 days prior to inclusion in this trial

          -  Any health problems which according to Investigator's clinical judgment will make the
             patient unsuitable for inclusion in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus Zachariae, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gentofte Amtssygehus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claus Zachariae, MD, Chief Physician</last_name>
    <phone>+4539773203</phone>
    <email>clza@geh.regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dermatology Clinic, Vesterbro</name>
      <address>
        <city>Aalborg</city>
        <zip>DK-9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Henrik Sølvsten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marselisborg University Hospital</name>
      <address>
        <city>Aarhus C</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mette S Deleuran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bispebjerg University Hospital</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>DK-2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Merete Hædersdal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gentoftte Amtssygehus</name>
      <address>
        <city>Hellerup</city>
        <zip>DK-2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claus Zachariae, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Henrik Lorentzen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2008</study_first_submitted>
  <study_first_submitted_qc>March 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2008</study_first_posted>
  <last_update_submitted>March 26, 2008</last_update_submitted>
  <last_update_submitted_qc>March 26, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2008</last_update_posted>
  <responsible_party>
    <name_title>NatImmune A/S</name_title>
    <organization>NatImmune</organization>
  </responsible_party>
  <keyword>wart</keyword>
  <keyword>cutaneous</keyword>
  <keyword>transplant</keyword>
  <keyword>Cutaneous warts in immune suppressed, kidney transplant patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

